We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.92B
AUM Growth
+$129M
Cap. Flow
+$265M
Cap. Flow %
13.75%
Top 10 Hldgs %
49.82%
Holding
94
New
22
Increased
32
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$65.4M
2
EW icon
Edwards Lifesciences
EW
+$64.1M
3
RAPP
Rapport Therapeutics
RAPP
+$45.2M
4
ALGN icon
Align Technology
ALGN
+$34.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$23M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$85.9M
2
INCY icon
Incyte
INCY
+$75.6M
3
ARGX icon
argenx
ARGX
+$58.8M
4
INBX
Inhibrx, Inc. Common Stock
INBX
+$45.5M
5
PODD icon
Insulet
PODD
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX icon
51
Inhibrx
INBX
$1.2B
$6.57M 0.34%
+463,315
New +$7.24M
ACHV icon
52
Achieve Life Sciences
ACHV
$626M
$6.53M 0.34%
1,388,372
-129,858
-9% -$626K
WAT icon
53
Waters Corp
WAT
$36.8B
$6.33M 0.33%
+21,804
New +$6.96M
JBIO
54
Jade Biosciences
JBIO
$1.22B
$6.24M 0.32%
107,391
– –
FDMT icon
55
4D Molecular Therapeutics
FDMT
$526M
$5.69M 0.3%
271,155
+72,969
+37% +$1.83M
MRNS
56
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.86M 0.25%
4,151,576
+2,750,523
+196% +$6.88M
NXTC icon
57
NextCure
NXTC
$17.3M
$4.25M 0.22%
222,655
– –
ERAS icon
58
Erasca
ERAS
$6.63B
$4.01M 0.21%
+1,699,528
New +$3.67M
PAHC icon
59
Phibro Animal Health
PAHC
$1.38B
$3.97M 0.21%
+237,009
New +$3.81M
BAX icon
60
Baxter International
BAX
$11.6B
$3.94M 0.2%
117,769
+97,769
+489% +$3.6M
AVTR icon
61
Avantor
AVTR
$7.81B
$2.99M 0.16%
141,045
-91,401
-39% -$2.2M
TFX icon
62
Teleflex
TFX
$5.85B
$2.87M 0.15%
13,649
+1,507
+12% +$316K
MASI
63
DELISTED
Masimo
MASI
$2.54M 0.13%
20,161
+161
+0.8% +$21.2K
BOLT icon
64
Bolt Biotherapeutics
BOLT
$7.36M
$2.07M 0.11%
137,722
– –
INSP icon
65
Inspire Medical Systems
INSP
$1.42B
$1.34M 0.07%
10,000
+1,901
+23% +$360K
IRON icon
66
Disc Medicine
IRON
$2.83B
$1.32M 0.07%
29,256
+23,083
+374% +$784K
CATX icon
67
Perspective Therapeutics
CATX
$332M
$1.32M 0.07%
132,089
+89,078
+207% +$1.29M
ZBH icon
68
Zimmer Biomet
ZBH
$17.7B
$1.15M 0.06%
+10,630
New +$1.25M
LIVN icon
69
LivaNova
LIVN
$4.3B
$1.13M 0.06%
20,602
+146
+0.7% +$8.32K
IMTXW
70
DELISTED
Immatics N.V. Warrants
IMTXW
$933K 0.05%
348,731
+32,382
+10% +$91K
RNAM
71
DELISTED
Avidity Biosciences
RNAM
$875K 0.05%
+21,425
New +$615K
IMA
72
ImageneBio Inc
IMA
$63.1M
$631K 0.03%
31,885
– –
SVRA icon
73
PUT
Savara
SVRA
$1.13B
$605K 0.03%
+150,000
New +$667K
AMLX icon
74
PUT
Amylyx Pharmaceuticals
AMLX
$2.05B
$570K 0.03%
300,000
– –
AMLX icon
75
Amylyx Pharmaceuticals
AMLX
$2.05B
$569K 0.03%
299,691
-7,038
-2% -$13.6K
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2024 Portfolio in Review

As of Q2 2024, Sofinnova Investments held 94 positions worth $1.92B, up 7.2% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments deployed $265M of net new capital in Q2 2024, opening 22 new positions and adding to 32 existing holdings. Its largest new stake was Stryker: 193,084 shares worth $65.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Insulet, an estimated $28.7M trimmed.

  • Sofinnova Investments's largest Q2 2024 buy was Stryker: 193,084 shares worth $65.7M.
  • Sofinnova Investments added most to Align Technology in Q2 2024, an estimated $34.3M increase.
  • Sofinnova Investments's biggest Q2 2024 reduction was Insulet, cutting an estimated $28.7M.
  • Sofinnova Investments fully exited Merck in Q2 2024, selling an estimated $85.9M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.92B portfolio in Q2 2024.
  • Sofinnova Investments opened 22 new positions and closed 13 in Q2 2024.
  • Sofinnova Investments's portfolio value rose 7.2% quarter-over-quarter to $1.92B.

Based on Sofinnova Investments's 13F filing for Q2 2024, filed 9 Aug 2024.